USA - NASDAQ:EDSA - CA27966L3065 - Common Stock
EDSA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. EDSA has a great financial health rating, but its profitability evaluates not so good. EDSA has a expensive valuation and it also scores bad on growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.98% | ||
| ROE | -41.89% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.39 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 18.97 | ||
| Quick Ratio | 18.97 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.73
+0.02 (+1.17%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.86 | ||
| P/tB | 1 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.98% | ||
| ROE | -41.89% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 18.97 | ||
| Quick Ratio | 18.97 | ||
| Altman-Z | 4.39 |
ChartMill assigns a fundamental rating of 3 / 10 to EDSA.
ChartMill assigns a valuation rating of 0 / 10 to EDESA BIOTECH INC (EDSA). This can be considered as Overvalued.
EDESA BIOTECH INC (EDSA) has a profitability rating of 1 / 10.
The financial health rating of EDESA BIOTECH INC (EDSA) is 8 / 10.
The Earnings per Share (EPS) of EDESA BIOTECH INC (EDSA) is expected to grow by 37.11% in the next year.